Entering text into the input field will update the search result below

FDA's Ad Comm backs approval of Intercept Pharma's OCA for

  • The FDA's Gastrointestinal Drugs Advisory Committee votes 17-0 backing approval of Intercept Pharmaceuticals' (ICPT) obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBA), accepting the use of the liver enzyme alkaline phosphatase (ALP) as a surrogate endpoint.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ICPT--
Intercept Pharmaceuticals, Inc.